James Patrick Allison
AdvisorDr. James Patrick Allison, Ph.D, also known as Jim, is Head of Scientific Advisory Board of Vironexis Biotherapeutics Inc. Dr. Allison is Member of Scientific Advisory Board of Hummingbird Bioscience Pte. Ltd. from June 2026. Dr. Allison serves as Venture Partner at Catalio Capital Management, LP. Dr. Allison serves as Member of Scientific Advisory Board at Akoya Biosciences Inc. since January 10, 2024. Dr. Allison serves as Member of Board of Advisor at InterVenn Biosciences Inc. since March 09, 2021. Dr. Allison serves as Member of Research Advisory Board at Candel Therapeutics, Inc. since April 2021. Dr. Allison serves as Member of Advisory Board at Lava Therapeutics NV since January 2020. Dr. Allison serves as Member of Scientific Advisory Board at Earli Inc. since January 2021. Dr. Allison serves as Member of Scientific Advisory Board at Lytix Biopharma ASA since June 2019. Dr. Allison serves as Member of Scientific Advisory Board at Forty-Seven, Inc. since October 03, 2018. Dr. Allison serves as Advisor at BioAtla, LLC since November 16, 2017. Dr. Allison serves as Co-Founder of Jounce Therapeutics and Neon. Dr. Allison serves as Advisors of Phenomic AI Inc. Dr. Allison serves as Founding Advisor and Chair of the Scientific Advisory Board of Apricity Health, LLC. Dr. Allison serves as Member of Scientific Advisory Board at Affini-T Therapeutics, Inc. Dr. Allison serves as Member of Scientific Advisory Board at Codiak BioSciences, Inc. Dr. Allison serves as Professor of Immunology at the University of California, Berkeley. Dr. Allison is Founder of BioNTech US Inc. At The University of Texas MD Anderson Cancer Center, Dr. Allison is Regental Professor and Chair of the Department of Immunology, the Olga Keith Wiess Distinguished University Chair for Cancer Research. Dr. Allison also serves as Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, Director of the Parker Institute for Cancer Research and Executive Director of the Immunotherapy Platform. At Memorial Sloan-Kettering Cancer Center, Dr. Allison serves as David H. Koch Chair in Immunologic Studies and Attending Immunologist. Dr. Allison is also Investigator with the Howard Hughes Medical Institute, Director of the Ludwig Center for Cancer Immunotherapy and Chair of the Immunology Program. Dr. Allison is Director of the Scientific Advisory Council at Cancer Research Institute, Inc. Ontario Institute for Cancer Research. Dr. Allison serves as Member of Scientific Advisory Board at Cellerant Therapeutics, Inc. Dr. Allison serves as Member of Advisory Board at Inimmune Corp. Dr. Allison is a Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Dr. Allison is a Member of the National Academy of Sciences and the Institute of Medicine. Dr. Allison was Member of the Scientific Advisory Board of TTxD BV until 2026. Dr. Allison served as Member of Dragonfly Scientific Advisory Board of Dragonfly Therapeutics, Inc. until November 2025. Dr. Allison had been a Member of Scientific Advisory Board at Marker Therapeutics, Inc. since May 22, 2018 until 2025. Dr. Allison was a Member of Scientific Advisory Board at Hummingbird Bioscience Pte. Ltd. until 2023. Dr. Allison served as Scientific Advisory Board Member of Tvardi Therapeutics, Inc until 2023. Dr. Allison served as a Member of Scientific Advisory Board at Xilis, Inc. since December 2022. Dr. Allison served as a Member of Scientific Advisory Board of Cerus Corporation since May 2004. Dr. Allison served as President of the American Association of Immunologists from 2001 to 2002. Dr. Allison served as Chairman of Department of Immunology at The University of Texas MD Anderson Cancer Center. Dr. Allison served as Associate Director of the Scientific Advisory Council at Cancer Research Institute, Inc. Dr. Allison served as a Member of Scientific Advisory Board at Heat Biologics, Inc. Dr. Allison served as a Member of Scientific Advisory Board at Kite Pharma, Inc. Dr. Allison served as a Member of Advisory Board of The Irvington Institute for Immunological Research of Business. Dr. Allison founded Jounce Therapeutics, Inc. in 2012. Dr. Allison focuses on understanding of the regulation of the early events in T-cell activation. Dr. Allison focuses on mechanisms of T-cell development and activation and the development of novel strategies for tumor immunotherapy. Research conducted by Dr. Allison led to the clinical development of ipilimumab, which was approved in 2011 by the FDA for the treatment of metastatic melanoma. Dr. Allison was the first person to isolate the T-cell antigen receptor protein. Dr. Allison was recipient of the 2018 Nobel Prize in Physiology or Medicine for the discovery of cancer therapy by inhibition of negative immune regulation. Dr. Allison completed a postdoctoral fellowship in molecular immunology at Scripps Clinic and Research Foundation. Dr. Allison received a Bachelor of Science in Biological Sciences and a Doctor of Philosophy in Biological Sciences from the University of Texas. Dr. Allison is a member of the National Academies of Science and Medicine and is currently Chair of the Department of Immunology, the Vivian L. Smith Distinguished Chair in Immunology, the Executive Director of the Immunotherapy Platform and Co-Director of the Parker Institute for Cancer Immunotherapy at MD Anderson Cancer Center.
Positions
- Company NameBioAtla, Inc.Stock CodeBCABPositionAdvisorColleagues
- JMJay M. ShortCo-Founder, CEO & Chairman
- CJChristian J. VasquezCFO & Corporate Secretary
- SMSusie MelodySenior Vice President of Human Resources
- CCCathy ChangSenior Vice President of Research & Development
- GFGerhard FreySenior Vice President of Technology Development
- LSLawrence SteinmanLead Independent Director
- MAMary Ann GrayIndependent Director
- SSSylvia S. McBrinnIndependent Director
